TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03422731

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of bone marrow and blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of bone marrow and blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-Energy Computed Tomography
Description: Undergo DECT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo FLT PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo water-fat MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FLT PET
Study: NCT04555655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peptide Supplement
Description: 70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.
Study: NCT02405039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005
Description: EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
Study: NCT02549820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
Description: Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
Study: NCT00121810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1.0-1.5 g oral dose twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil [CellCept]
Description: 1.0-1.5 g oral dose twice daily
Study: NCT06689111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing lead
Description: Use of LBBp Vs the standard method of BiVp in resynchronization therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT with the standard method through cs
Description: standard CRT procedure
Study: NCT00121810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: As prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: As prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitors
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: As prescribed
Study: NCT04222127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EUS guided injection of gastric varices by CYA
Description: EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate \& lipidol using 19G EUS-FNA needle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct endoscopic injection of gastric varices by CYA
Description: Direct endoscopic injection of gastric varix by CYA
Study: NCT02481518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
Study: NCT04292119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be taken orally twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: TNO155 will be taken orally once daily for 14 days.
Study: NCT02747043

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABP 798
Description: ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100-mg/10 mL or 500-mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
Study: NCT02237053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Study: NCT01398761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Signout tool
Description: Electronic signout tool
Study: NCT06685939

Intervention type: PROCEDURE
Intervention: LPD
Description: The patients who received the LPD
Study: NCT03431805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Solution
Description: After the routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the woman within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: After a routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes afterbirth), slowly (over 30-60 seconds), once the cord has been clamped.
Study: NCT02150044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Tympanostomy Tube Delivery System (TTDS).
Description: tympanostomy tube delivery system
Study: NCT02015533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR8020
Description: CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
Study: NCT02764125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa MR
Description: levodopa MR/carbidopa/ODM-104
Study: NCT03895242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1:Supine-Prone
Description: After the infants were treated and fed, supine position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in supine position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the supine positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the prone position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the prone position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2:Prone-Supine
Description: After the infants were treated and fed, prone position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in prone position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the supine position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the supine position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
Study: NCT02015533

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single 2-hour intravenous infusion.
Study: NCT00636714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing judgement
Description: Based on the nursing judgement, titrate insulin infusion and determine glucose check frequency to achieve a target glucose of 5-8 mmol/L

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nomogram
Description: A preprinted order outlining a nomogram with instructions for how insulin infusion should be changed based on measured glucose values and how frequent the glucose checks should be
Study: NCT01968161

Intervention type: DRUG
Group type: OTHER
Intervention: Asenapine
Study: NCT01719861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine HCL
Description: Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
Study: NCT02448719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 30 mg
Description: TAK-792 30 mg was administered in the morning after a fast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 30 mg placebo
Description: TAK-792 30 mg placebo was administered in the morning after a fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 100 mg
Description: TAK-792 100 mg was administered in the morning after a fast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 100 mg placebo
Description: TAK-792 100 mg placebo was administered in the morning after a fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 250 mg
Description: TAK-792 250 mg was administered in the morning after a fast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 250 mg placebo
Description: TAK-792 250 mg placebo was administered in the morning after a fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 500 mg
Description: TAK-792 500 mg was administered in the morning after a fast or after breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 500 mg placebo
Description: TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 750 mg
Description: TAK-792 750 mg was administered in the morning after a fast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 750 mg placebo
Description: TAK-792 750 mg placebo was administered in the morning after a fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-792 1250 mg
Description: TAK-792 1250 mg was administered in the morning after a fast.
Study: NCT02237053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Study: NCT02448719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-792 1250 mg placebo
Description: TAK-792 1250 mg placebo was administered in the morning after a fast.
Study: NCT02237053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octreotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octreotide

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Study: NCT05348187

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: therascreen® KRAS RGQ PCR Kit
Description: The primary objective is to utilize a clinical trial assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 2 of Amgen clinical trial, in order to identify patients (with NSCLC and CRC) with KRAS G12C mutation positive tumors
Study: NCT01232556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: 1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
Study: NCT00260078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 200 mg to 400 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 300 mg or 600 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Dosage dependent on participant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Dosage dependent on participant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Dosage dependent on participant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Dosage dependent on participant
Study: NCT01083329

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: training
Description: the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
Study: NCT01232556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab + gemcitabine
Description: rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab +bendamustine
Description: rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
Study: NCT01083329

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: training
Description: the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotinic acid
Description: Obese subjects will receive nicotinic acid or placebo for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Obese subjects will receive nicotinic acid or placebo for 16 weeks
Study: NCT03464396

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: A non-sedating MRI scan will be performed on 3 subsets of infants at 37-40 weeks Post Menstrual Age (PMA), or when infant is within one week of discharge from the NICU. Standard images as well as research images will be obtained. The research images use the same MRI scanner and collection techniques as standard clinical imaging, but provide a more detailed examination of brain anatomy and injury. Collection of these sequences using our standard non-sedated acquisition practices for infants is well tolerated. Infants will be placed in scanner by registered nurse accompanied by radiology technician to assure infants' comfort during scan. Infant will remain on cardio-respiratory monitor during MRI via a pulse oximetry probe. It will take no longer than one hour to complete MRI scan including transportation to radiology unit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: An echocardiogram (referred to as an ultrasound of the heart on the consent form) will be performed to assess cardiac structure and function. Echocardiograms are performed routinely in premature newborns in the NICU. The Echocardiogram will be performed at the infant bedside and will be coordinated with bedside nurse. The infant will remain on a cardio-respiratory monitor during the echocardiogram for approximately 15 minutes.

Intervention type: OTHER
Intervention: Blood Sample
Description: Infants that have echocardiograms will have a blood sample collected near the time the echocardiogram is obtained, 3-blood samples total. The blood sample will only be collected with parental permission on an opt-in or out-basis and collected only with routine clinical labs.
Study: NCT03379636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesiotape
Description: Application of an elastic beige 5-cm width Leukotape®K (BSN medical, Germany). The first strip, a Y-strip, was applied with 10% to 15% of tension over the deltoid muscle, from origin to insertion with the first tail along the anterior deltoid while the arm was externally rotated and horizontally abducted. The second tail was applied along the posterior deltoid with the arm horizontally adducted and internally rotated. A second strip, an I-strip, was applied for mechanical correction, transversally in the sagittal plane over the acromioclavicular joint with a downward pressure applied to the KT, the arm being at trunk side

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tape
Description: a rigid Leukotape®Classic (BSN medical, Germany) was used. A 5-cm strip was applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area.
Study: NCT03235141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin eye drops by essex
Description: azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin eye drops by essex
Description: azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin eye drops
Description: azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin eye drops
Description: azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
Study: NCT02818894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Spinal anesthesia administered prior to participant's THA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Spinal anesthesia administered prior to participant's THA
Study: NCT02201316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference mosapride citrate (GASMOTIN)
Description: Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference mosapride citrate (GASMOTIN)
Description: Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference mosapride citrate (GASMOTIN)
Description: Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
Study: NCT00260078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 50 mg or 100 mg orally twice daily
Study: NCT00759707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-N^G monomethyl arginine (L-NMMA)
Description: L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein \[arterial\] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
Study: NCT01656876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror box training
Description: This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror box training
Description: This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mesh glove stimulation
Description: The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional intervention
Description: Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
Study: NCT02642809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biopsy
Study: NCT04086173

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics will be administered at night and will consist of 4 capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo